Lorazepam
- Generic Name
- Lorazepam
- Brand Names
- Ativan, Loreev
- Drug Type
- Small Molecule
- Chemical Formula
- C15H10Cl2N2O2
- CAS Number
- 846-49-1
- Unique Ingredient Identifier
- O26FZP769L
- Background
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
- Indication
Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
...
- Associated Conditions
- Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
- Associated Therapies
- Anesthetic premedication therapy
Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Maria Pacella
- Target Recruit Count
- 1
- Registration Number
- NCT03756038
- Locations
- 🇺🇸
UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT03743649
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
🇧🇷Hosptial de Cancer de Barretos, Barretos, Sao Paulo, Brazil
Post Operative Pain Control After Pediatric Hip Surgery
- Conditions
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT03435692
Assessment of Valproate on Ethanol Withdrawal
- Conditions
- Interventions
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- CAMC Health System
- Target Recruit Count
- 210
- Registration Number
- NCT03235531
- Locations
- 🇺🇸
Charleston Area Medical Center, Charleston, West Virginia, United States
🇺🇸Charleston Area Medical Center, General Hospital, Level 1 Trauma Center, Charleston, West Virginia, United States
Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy:
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- St. Justine's Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT03180632
- Locations
- 🇨🇦
CHU Sainte-Justine, Montréal, Quebec, Canada
Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 19
- Registration Number
- NCT03090620
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, Colorado, United States
A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 46
- Registration Number
- NCT03021018
- Locations
- 🇺🇸
Ep0087 108, Birmingham, Alabama, United States
🇺🇸Ep0087 117, Tucson, Arizona, United States
🇺🇸Ep0087 112, Orlando, Florida, United States
PF-06372865 in Subjects With Photosensitive Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7
- Registration Number
- NCT02564029
- Locations
- 🇺🇸
Consultants in Epilepsy & Neurology, PLLC, Boise, Idaho, United States
🇺🇸Hospital of the Univ of PA Pharmacy Service, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital EEG lab, Philadelphia, Pennsylvania, United States
Catatonia in Nodding Syndrome and Lorazepam Treatment
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 16
- Registration Number
- NCT02462109
A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- Kirk Erickson, PhD
- Target Recruit Count
- 31
- Registration Number
- NCT02407704
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.